{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:10:08Z","timestamp":1778724608951,"version":"3.51.4"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>There is growing evidence that psychedelics and associated treatment modalities may offer therapeutic benefits across a range of psychiatric conditions. Anorexia nervosa (AN), a serious and often treatment-resistant illness associated with significant morbidity and mortality, is one such condition for which psilocybin-assisted therapy (PAT) may hold promise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>To date, research on PAT for AN has focused primarily on adults, despite the fact that AN frequently begins in adolescence, and early age of onset portends poorer prognosis, including more severe AN, more lifetime psychiatric comorbidity, and greater life difficulties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Given these risks, an exploration of the theoretical potential of PAT for adolescent populations is warranted. Important considerations include biological implications, developmental stage, and consent. Adaptations to the current models of psilocybin-assisted therapy in studies of adults are proposed, and emerging models that address the unique challenges of these patients are discussed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11920-026-01679-z","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:55:03Z","timestamp":1778723703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9049-4400","authenticated-orcid":false,"given":"Jamarie A.","family":"Geller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-267X","authenticated-orcid":false,"given":"Rachel","family":"Pacilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-7798","authenticated-orcid":false,"given":"Amanda E.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-3428","authenticated-orcid":false,"given":"Anya","family":"Ragnhildstveit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-8970","authenticated-orcid":false,"given":"Marissa","family":"Raymond-Flesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9421-9158","authenticated-orcid":false,"given":"Stephanie","family":"Knatz-Peck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-1421","authenticated-orcid":false,"given":"Natalie","family":"Gukasyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"10","key":"1679_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1177\/02698811241269751","volume":"38","author":"K Madden","year":"2024","unstructured":"Madden K, Flood B, Young Shing D, et al. Psilocybin for clinical indications: A scoping review. J Psychopharmacol. 2024;38(10):839\u201345. https:\/\/doi.org\/10.1177\/02698811241269751.","journal-title":"J Psychopharmacol"},{"key":"1679_CR2","doi-asserted-by":"publisher","first-page":"115531","DOI":"10.1016\/j.psychres.2023.115531","volume":"329","author":"S Haikazian","year":"2023","unstructured":"Haikazian S, Chen-Li DCJ, Johnson DE, et al. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Res. 2023;329:115531. https:\/\/doi.org\/10.1016\/j.psychres.2023.115531.","journal-title":"Psychiatry Res"},{"key":"1679_CR3","doi-asserted-by":"publisher","first-page":"116337","DOI":"10.1016\/j.psychres.2025;116337","volume":"344","author":"D Swieczkowski","year":"2025","unstructured":"Swieczkowski D, Kwa\u015bny A, Pruc M, Gaca Z, Szarpak L, Cuba\u0142a WJ. Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials. Psychiatry Res. 2025;344:116337. https:\/\/doi.org\/10.1016\/j.psychres.2025;116337.","journal-title":"Psychiatry Res"},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"1406888","DOI":"10.3389\/fpsyt.2024.1406888","volume":"15","author":"S Szafoni","year":"2024","unstructured":"Szafoni S, Gr\u0119blowski P, Grabowska K, Wi\u0119ckiewicz G. Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder. Front Psychiatry. 2024;15:1406888. https:\/\/doi.org\/10.3389\/fpsyt.2024.1406888. Published 2024 Jun 11.","journal-title":"Front Psychiatry"},{"key":"1679_CR5","doi-asserted-by":"publisher","first-page":"e20220597","DOI":"10.47626\/2237-6089-2022-0597","volume":"46","author":"E Koning","year":"2024","unstructured":"Koning E, Brietzke E. Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence. Trends Psychiatry Psychother. 2024;46:e20220597. https:\/\/doi.org\/10.47626\/2237-6089-2022-0597.","journal-title":"Trends Psychiatry Psychother"},{"issue":"6","key":"1679_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320. https:\/\/doi.org\/10.1177\/0269881108093587.","journal-title":"J Psychopharmacol"},{"key":"1679_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0022167817706884","volume":"57","author":"AB Belser","year":"2017","unstructured":"Belser AB, Agin-Liebes G, Swift TC, et al. Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol. 2017;57:354\u201388.","journal-title":"J Humanist Psychol"},{"key":"1679_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40337-024-01125-6","volume":"12","author":"E Lacroix","year":"2024","unstructured":"Lacroix E, Fatur K, Hay P, et al. Psychedelics and the treatment of eating disorders: considerations for future research and practice. J Eat Disord. 2024;12:165. https:\/\/doi.org\/10.1186\/s40337-024-01125-6.","journal-title":"J Eat Disord"},{"key":"1679_CR9","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"10","key":"1679_CR10","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","volume":"49","author":"KR Merikangas","year":"2010","unstructured":"Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication\u2014Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980\u20139. https:\/\/doi.org\/10.1016\/j.jaac.2010.05.017.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"1679_CR11","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archgenpsychiatry.2011.22","volume":"68","author":"SA Swanson","year":"2011","unstructured":"Swanson SA, Crow SJ, Le Grange D, Swendsen J, Merikangas KR. Prevalence and correlates of eating disorders in adolescents: results from the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. 2011;68(7):714\u201323. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.22.","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"1679_CR12","doi-asserted-by":"publisher","first-page":"e1912925","DOI":"10.1001\/jamanetworkopen.2019.12925","volume":"2","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Rodriguez P, Wright DR, Austin SB, Long MW. Estimation of eating disorders prevalence by age and associations with mortality in a simulated nationally representative US cohort. JAMA Netw Open. 2019;2(10):e1912925. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.12925.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1679_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.12740\/PP\/64580","volume":"51","author":"G Jagielska","year":"2017","unstructured":"Jagielska G, Kacperska I. Outcome, comorbidity and prognosis in anorexia nervosa. Psychiatr Pol. 2017;51(2):205\u201318. https:\/\/doi.org\/10.12740\/PP\/64580.","journal-title":"Psychiatr Pol"},{"issue":"9","key":"1679_CR14","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/eat.23580","volume":"54","author":"CM Grilo","year":"2021","unstructured":"Grilo CM, Udo T. Examining the significance of age of onset in persons with lifetime anorexia nervosa: comparing child, adolescent, and emerging adult onsets in nationally representative U.S. study. Int J Eat Disord. 2021;54(9):1632\u201340. https:\/\/doi.org\/10.1002\/eat.23580.","journal-title":"Int J Eat Disord"},{"key":"1679_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s40337-024-01130-9","volume":"12","author":"A Ayrolles","year":"2024","unstructured":"Ayrolles A, Clarke J, Godart N, et al. Early-onset anorexia nervosa: a scoping review and management guidelines. J Eat Disord. 2024;12:182. https:\/\/doi.org\/10.1186\/s40337-024-01130-9.","journal-title":"J Eat Disord"},{"issue":"10","key":"1679_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/eip.13392","volume":"17","author":"J Pruccoli","year":"2023","unstructured":"Pruccoli J, Parmeggiani A. Early onset anorexia nervosa: multidisciplinary hospital intervention in a 1-year follow-up study. Early Interv Psychiatry. 2023;17(10):992\u20131000. https:\/\/doi.org\/10.1111\/eip.13392.","journal-title":"Early Interv Psychiatry"},{"key":"1679_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40337-023-00779-y","volume":"11","author":"C Brennan","year":"2023","unstructured":"Brennan C, Illingworth S, Cini E, et al. Medical instability in typical and atypical adolescent anorexia nervosa: a systematic review and meta-analysis. J Eat Disord. 2023;11:58. https:\/\/doi.org\/10.1186\/s40337-023-00779-y.","journal-title":"J Eat Disord"},{"issue":"5","key":"1679_CR18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jadohealth.2022.08.006","volume":"71","author":"Society for Adolescent Health and Medicine","year":"2022","unstructured":"Society for Adolescent Health and Medicine. Medical management of restrictive eating disorders in adolescents and young adults. J Adolesc Health. 2022;71(5):648\u201354. https:\/\/doi.org\/10.1016\/j.jadohealth.2022.08.006.","journal-title":"J Adolesc Health"},{"key":"1679_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40337-023-00759-2","volume":"11","author":"AB Tanner","year":"2023","unstructured":"Tanner AB. Unique considerations for the medical care of restrictive eating disorders in children and young adolescents. J Eat Disord. 2023;11:33. https:\/\/doi.org\/10.1186\/s40337-023-00759-2.","journal-title":"J Eat Disord"},{"key":"1679_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.12974\/2311-8687.2024.12.13","volume":"12","author":"G Fiacco","year":"2024","unstructured":"Fiacco G, Catone G, Salerno F, Gritti A, Gleijeses M, Carotenuto M. Internalizing psychiatric comorbidities among adolescents with anorexia nervosa. Int J Pediatr Child Health. 2024;12:98\u2013105. https:\/\/doi.org\/10.12974\/2311-8687.2024.12.13.","journal-title":"Int J Pediatr Child Health"},{"issue":"8","key":"1679_CR21","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1176\/appi.ajp.159.8.1284","volume":"159","author":"HC Steinhausen","year":"2002","unstructured":"Steinhausen HC. The outcome of anorexia nervosa in the 20th century. Am J Psychiatry. 2002;159(8):1284\u201393. https:\/\/doi.org\/10.1176\/appi.ajp.159.8.1284.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1679_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/eat.22501","volume":"49","author":"MM Fichter","year":"2016","unstructured":"Fichter MM, Quadflieg N. Mortality in eating disorders\u2014results of a large prospective clinical longitudinal study. Int J Eat Disord. 2016;49(4):391\u2013401. https:\/\/doi.org\/10.1002\/eat.22501.","journal-title":"Int J Eat Disord"},{"issue":"1","key":"1679_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1192\/bjp.bp.108.054742","volume":"194","author":"FC Papadopoulos","year":"2009","unstructured":"Papadopoulos FC, Ekbom A, Brandt L, Ekselius L. Excess mortality, causes of death and prognostic factors in anorexia nervosa. Br J Psychiatry. 2009;194(1):10\u20137. https:\/\/doi.org\/10.1192\/bjp.bp.108.054742.","journal-title":"Br J Psychiatry"},{"key":"1679_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40479-023-00216-1","volume":"10","author":"S Arnold","year":"2023","unstructured":"Arnold S, Correll CU, Jaite C. Frequency and correlates of lifetime suicidal ideation and suicide attempts among consecutively hospitalized youth with anorexia nervosa and bulimia nervosa: results from a retrospective chart review. Borderline Personal Disord Emot Dysregul. 2023;10:10. https:\/\/doi.org\/10.1186\/s40479-023-00216-1.","journal-title":"Borderline Personal Disord Emot Dysregul"},{"issue":"5","key":"1679_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/bs11050078","volume":"11","author":"RS Patel","year":"2021","unstructured":"Patel RS, Machado T, Tankersley WE. Eating disorders and suicidal behaviors in adolescents with major depression: insights from the US hospitals. Behav Sci (Basel). 2021;11(5):78. https:\/\/doi.org\/10.3390\/bs11050078.","journal-title":"Behav Sci (Basel)"},{"key":"1679_CR26","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.3389\/fpsyg.2017.02273","volume":"8","author":"EC Gregertsen","year":"2017","unstructured":"Gregertsen EC, Mandy W, Serpell L. The egosyntonic nature of anorexia: an impediment to recovery in anorexia nervosa treatment. Front Psychol. 2017;8:2273. https:\/\/doi.org\/10.3389\/fpsyg.2017.02273.","journal-title":"Front Psychol"},{"issue":"7","key":"1679_CR27","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/archgenpsychiatry.2011.74","volume":"68","author":"J Arcelus","year":"2011","unstructured":"Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch Gen Psychiatry. 2011;68(7):724\u201331. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.74.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1679_CR28","first-page":"207","volume":"51","author":"J Lock","year":"2010","unstructured":"Lock J. Treatment of adolescent eating disorders: progress and challenges. Minerva Psichiatr. 2010;51(3):207\u201316.","journal-title":"Minerva Psichiatr"},{"issue":"6","key":"1679_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/YCO.0b013e328365a30e","volume":"26","author":"AE Kass","year":"2013","unstructured":"Kass AE, Kolko RP, Wilfley DE. Psychological treatments for eating disorders. Curr Opin Psychiatry. 2013;26(6):549\u201355. https:\/\/doi.org\/10.1097\/YCO.0b013e328365a30e.","journal-title":"Curr Opin Psychiatry"},{"key":"1679_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.brat.2014.03.006","volume":"56","author":"D Le Grange","year":"2014","unstructured":"Le Grange D, Fitzsimmons-Craft EE, Crosby RD, et al. Predictors and moderators of outcome for severe and enduring anorexia nervosa. Behav Res Ther. 2014;56:91\u20138. https:\/\/doi.org\/10.1016\/j.brat.2014.03.006.","journal-title":"Behav Res Ther"},{"issue":"2","key":"1679_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/eat.23867","volume":"56","author":"N Datta","year":"2023","unstructured":"Datta N, Hagan K, Bohon C, et al. Predictors of family-based treatment for adolescent eating disorders: do family or diagnostic factors matter? Int J Eat Disord. 2023;56(2):384\u201393. https:\/\/doi.org\/10.1002\/eat.23867.","journal-title":"Int J Eat Disord"},{"issue":"4","key":"1679_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1017\/S0033291718002088","volume":"49","author":"SB Murray","year":"2019","unstructured":"Murray SB, Quintana DS, Loeb KL, Griffiths S, Le Grange D. Treatment outcomes for anorexia nervosa: a systematic review and meta-analysis of randomized controlled trials. Psychol Med. 2019;49(4):535\u201344. https:\/\/doi.org\/10.1017\/S0033291718002088.","journal-title":"Psychol Med"},{"issue":"2","key":"1679_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1017\/S0033291721001604","volume":"53","author":"KE Hagan","year":"2023","unstructured":"Hagan KE, Matheson BE, Datta N, et al. Understanding outcomes in family-based treatment for adolescent anorexia nervosa: a network approach. Psychol Med. 2023;53(2):396\u2013407. https:\/\/doi.org\/10.1017\/S0033291721001604.","journal-title":"Psychol Med"},{"key":"1679_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/erv.2240","volume":"21","author":"M Balestrieri","year":"2013","unstructured":"Balestrieri M, Oriani MG, Simoncini A, Bellantuono C. Psychotropic drug treatment in anorexia nervosa: search for differences in efficacy\/tolerability between adolescent and mixed-age population. Eur Eat Disord Rev. 2013;21:361\u201373. https:\/\/doi.org\/10.1002\/erv.2240.","journal-title":"Eur Eat Disord Rev"},{"key":"1679_CR35","doi-asserted-by":"publisher","first-page":"1259038","DOI":"10.3389\/frcha.2024.1259038","volume":"3","author":"S Jaka","year":"2024","unstructured":"Jaka S, Pokhrel S, Patel A, et al. Demographics, psychiatric comorbidities, and hospital outcomes across eating disorder types in adolescents and youth: insights from US hospitals data. Front Child Adolesc Psychiatry. 2024;3:1259038. https:\/\/doi.org\/10.3389\/frcha.2024.1259038.","journal-title":"Front Child Adolesc Psychiatry"},{"key":"1679_CR36","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2165\/00023210-200620080-00004","volume":"20","author":"BD Woodside","year":"2006","unstructured":"Woodside BD, Staab R. Management of psychiatric comorbidity in anorexia nervosa and bulimia nervosa. CNS Drugs. 2006;20:655\u201363. https:\/\/doi.org\/10.2165\/00023210-200620080-00004.","journal-title":"CNS Drugs"},{"issue":"1","key":"1679_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jadohealth.2015.03.021","volume":"57","author":"MC Monge","year":"2015","unstructured":"Monge MC, Forman SF, McKenzie NM, et al. Use of psychopharmacologic medications in adolescents with restrictive eating disorders: analysis of data from the National Eating Disorder Quality Improvement Collaborative. J Adolesc Health. 2015;57(1):66\u201372. https:\/\/doi.org\/10.1016\/j.jadohealth.2015.03.021.","journal-title":"J Adolesc Health"},{"issue":"6","key":"1679_CR38","first-page":"43","volume":"2","author":"K Gorla","year":"2005","unstructured":"Gorla K, Mathews M. Pharmacological treatment of eating disorders. Psychiatry (Edgmont). 2005;2(6):43\u20138.","journal-title":"Psychiatry (Edgmont)"},{"key":"1679_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40337-023-00833-9","volume":"11","author":"SC Rodan","year":"2023","unstructured":"Rodan SC, Bryant E, Le A, et al. Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review. J Eat Disord. 2023;11:112. https:\/\/doi.org\/10.1186\/s40337-023-00833-9.","journal-title":"J Eat Disord"},{"issue":"4","key":"1679_CR40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/YCT.0000000000000418","volume":"33","author":"LM Andersen","year":"2017","unstructured":"Andersen LM, LaRosa C, Gih DE. Reexamining the role of electroconvulsive therapy in anorexia nervosa in adolescents. J ECT. 2017;33(4):294\u20136. https:\/\/doi.org\/10.1097\/YCT.0000000000000418.","journal-title":"J ECT"},{"issue":"2","key":"1679_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/cap.2014.2422","volume":"24","author":"JT Andrews","year":"2014","unstructured":"Andrews JT, Seide M, Guarda AS, Redgrave GW, Coffey DB. Electroconvulsive therapy in an adolescent with severe major depression and anorexia nervosa. J Child Adolesc Psychopharmacol. 2014;24(2):94\u20138. https:\/\/doi.org\/10.1089\/cap.2014.2422.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"1679_CR42","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/YCT.0000000000000599","volume":"35","author":"RM Pacilio","year":"2019","unstructured":"Pacilio RM, Livingston RK, Gordon MR. The use of electroconvulsive therapy in eating disorders: a systematic literature review and case report. J ECT. 2019;35(4):272\u20138. https:\/\/doi.org\/10.1097\/YCT.0000000000000599.","journal-title":"J ECT"},{"issue":"8","key":"1679_CR43","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3390\/jcm9082358","volume":"9","author":"P Duriez","year":"2020","unstructured":"Duriez P, Bou Khalil R, Chamoun Y, et al. Brain stimulation in eating disorders: state of the art and future perspectives. J Clin Med. 2020;9(8):2358. https:\/\/doi.org\/10.3390\/jcm9082358.","journal-title":"J Clin Med"},{"issue":"3","key":"1679_CR44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/brainsci12030382","volume":"12","author":"A Ragnhildstveit","year":"2022","unstructured":"Ragnhildstveit A, Slayton M, Jackson LK, et al. Ketamine as a novel psychopharmacotherapy for eating disorders: evidence and future directions. Brain Sci. 2022;12(3):382. https:\/\/doi.org\/10.3390\/brainsci12030382.","journal-title":"Brain Sci"},{"issue":"1","key":"1679_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40337-025-01232-y","volume":"13","author":"PJ Escobedo-Aedo","year":"2025","unstructured":"Escobedo-Aedo PJ, Serrand C, Kabani S, Estric C. Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis. J Eat Disord. 2025;13(1):48.","journal-title":"J Eat Disord"},{"issue":"1","key":"1679_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40337-025-01313-y","volume":"13","author":"CL Dahlgren","year":"2025","unstructured":"Dahlgren CL, Tverrli E, Stewart LH. Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa. J Eat Disord. 2025;13(1):107.","journal-title":"J Eat Disord"},{"issue":"2","key":"1679_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/shm\/hkl039","volume":"19","author":"E Dyck","year":"2006","unstructured":"Dyck E. Hitting Highs at Rock Bottom\u2019: LSD treatment for alcoholism, 1950\u20131970. Soc Hist Med. 2006;19(2):313\u201329. https:\/\/doi.org\/10.1093\/shm\/hkl039.","journal-title":"Soc Hist Med"},{"issue":"12","key":"1679_CR48","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"30","author":"JJ Rucker","year":"2016","unstructured":"Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol. 2016;30(12):1220\u20139. https:\/\/doi.org\/10.1177\/0269881116679368.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1679_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289\u201399. https:\/\/doi.org\/10.1177\/0269881114565144.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"1679_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"1679_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, et al. Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Arch Gen Psychiatry. 2011;68(1):71\u20138. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.116.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"1679_CR52","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983\u201392. https:\/\/doi.org\/10.1177\/0269881114548296.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"1679_CR53","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165\u201380. https:\/\/doi.org\/10.1177\/0269881116675512.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1679_CR54","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1192\/j.eurpsy.2024.1806","volume":"68","author":"M Destoop","year":"2025","unstructured":"Destoop M, Mohr P, Butlen F, et al. Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper. Eur Psychiatry. 2025;68(1):e3. https:\/\/doi.org\/10.1192\/j.eurpsy.2024.1806. Published 2025 Jan 10.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"1679_CR55","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/1363461520983684","volume":"59","author":"N Gukasyan","year":"2021","unstructured":"Gukasyan N, Nayak SM. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Transcult Psychiatry. 2021;59(5):652\u201364. https:\/\/doi.org\/10.1177\/1363461520983684.","journal-title":"Transcult Psychiatry"},{"issue":"9","key":"1679_CR56","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(9):1133\u201352. https:\/\/doi.org\/10.1080\/17512433.2021.1933434.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1679_CR57","doi-asserted-by":"publisher","unstructured":"Yaden DB, Graziosi M, Owen AM, Agin-Liebes G, Aaronson ST, Allen KE, Barrett FS, Bogenschutz MP, Carhart-Harris R, Ching THW, Cosimano MP, Danforth A, Davis AK, Garcia-Romeu A, Griffiths R, Grob CS, Gr\u00fcnder G, Gukasyan N, Heinzerling KG, Yaden ME. A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. Psychedelic medicine (New Rochelle, N.Y.). 2025;3(1), 1\u201318. https:\/\/doi.org\/10.1089\/psymed.2024.0019","DOI":"10.1089\/psymed.2024.0019"},{"issue":"10","key":"1679_CR58","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","volume":"7","author":"B Anderson","year":"2020","unstructured":"Anderson B, Danforth A, Grob C. Psychedelic medicine: Safety and ethical concerns. Lancet Psychiatry. 2020;7(10):829\u201330. https:\/\/doi.org\/10.1016\/S2215-0366(20)30146-2.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"1679_CR59","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","volume":"51","author":"A Trope","year":"2019","unstructured":"Trope A, Anderson BT, Hooker AR, Glick G, Stauffer C, Woolley JD. Psychedelic-Assisted Group Therapy: A Systematic Review. J Psychoact Drugs. 2019;51(2):174\u201388. https:\/\/doi.org\/10.1080\/02791072.2019.1593559.","journal-title":"J Psychoact Drugs"},{"issue":"7","key":"1679_CR60","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1328\u201334. https:\/\/doi.org\/10.1038\/s41386-019-0324-9.","journal-title":"Neuropsychopharmacology"},{"key":"1679_CR61","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3389\/fnhum.2016.00600","volume":"10","author":"G Riva","year":"2016","unstructured":"Riva G. Neurobiology of Anorexia Nervosa: Serotonin Dysfunctions Link Self-Starvation with Body Image Disturbances through an Impaired Body Memory. Front Hum Neurosci. 2016;10:600. https:\/\/doi.org\/10.3389\/fnhum.2016.00600. Published 2016 Nov 24.","journal-title":"Front Hum Neurosci"},{"issue":"1","key":"1679_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1139\/jpn.0403","volume":"29","author":"H Steiger","year":"2004","unstructured":"Steiger H. Eating disorders and the serotonin connection: state, trait and developmental effects. J Psychiatry Neurosci. 2004;29(1):20\u20139.","journal-title":"J Psychiatry Neurosci"},{"key":"1679_CR63","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrn2682","volume":"10","author":"W Kaye","year":"2009","unstructured":"Kaye W, Fudge J, Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nat Rev Neurosci. 2009;10:573\u201384. https:\/\/doi.org\/10.1038\/nrn2682.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"1679_CR64","first-page":"163","volume":"44","author":"K Audenaert","year":"2003","unstructured":"Audenaert K, Van Laere K, Dumont F, et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med. 2003;44(2):163\u20139.","journal-title":"J Nucl Med"},{"issue":"9","key":"1679_CR65","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0006-3223(02)01378-1","volume":"52","author":"GK Frank","year":"2002","unstructured":"Frank GK, Kaye WH, Meltzer CC, et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry. 2002;52(9):896\u2013906. https:\/\/doi.org\/10.1016\/s0006-3223(02)01378-1.","journal-title":"Biol Psychiatry"},{"key":"1679_CR66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40519-024-01659-3","volume":"29","author":"A Bevilacqua","year":"2024","unstructured":"Bevilacqua A, Santini F, La Porta D, et al. Association of serotonin receptor gene polymorphisms with anorexia nervosa: a systematic review and meta-analysis. Eat Weight Disord. 2024;29:31. https:\/\/doi.org\/10.1007\/s40519-024-01659-3.","journal-title":"Eat Weight Disord"},{"issue":"1","key":"1679_CR67","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/02698811211026454","volume":"36","author":"DE-W McCulloch","year":"2021","unstructured":"McCulloch DE-W, Madsen MK, Stenb\u00e6k DS, et al. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. J Psychopharmacol. 2021;36(1):74\u201384. https:\/\/doi.org\/10.1177\/02698811211026454.","journal-title":"J Psychopharmacol"},{"key":"1679_CR68","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fnbeh.2014.00346","volume":"8","author":"I Boehm","year":"2014","unstructured":"Boehm I, Geisler D, King JA, Ritschel F, Seidel M, Deza Araujo Y, Petermann J, Lohmeier H, Weiss J, Walter M, Roessner V, Ehrlich S. Increased resting state functional connectivity in the fronto-parietal and default mode network in anorexia nervosa. Front Behav Neurosci. 2014;8:346. https:\/\/doi.org\/10.3389\/fnbeh.2014.00346.","journal-title":"Front Behav Neurosci"},{"key":"1679_CR69","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jcpp.13970","volume":"65","author":"I Boehm","year":"2024","unstructured":"Boehm I, Mennigen E, Geisler D, Poller NW, Gramatke K, Calhoun VD, Roessner V, King JA, Ehrlich S. Dynamic functional connectivity in anorexia nervosa: alterations in states of low connectivity and state transitions. J Child Psychol Psychiatr. 2024;65:1299\u2013310. https:\/\/doi.org\/10.1111\/jcpp.13970.","journal-title":"J Child Psychol Psychiatr"},{"key":"1679_CR70","doi-asserted-by":"publisher","first-page":"103745","DOI":"10.1016\/j.nicl.2025.103745","volume":"45","author":"KFM Brack\u00e9","year":"2025","unstructured":"Brack\u00e9 KFM, Rente Dias LM, Meijer MN, et al. Resting-state functional brain connectivity in female adolescents with first-onset anorexia nervosa. Neuroimage Clin. 2025;45:103745. https:\/\/doi.org\/10.1016\/j.nicl.2025.103745.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"1679_CR71","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1503\/jpn.140310","volume":"41","author":"D Geisler","year":"2016","unstructured":"Geisler D, Borchardt V, Lord AR, et al. Abnormal functional global and local brain connectivity in female patients with anorexia nervosa. J Psychiatry Neurosci. 2016;41(1):6\u201315. https:\/\/doi.org\/10.1503\/jpn.140310.","journal-title":"J Psychiatry Neurosci"},{"issue":"4","key":"1679_CR72","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.bpsc.2024.01.006","volume":"9","author":"M Seidel","year":"2024","unstructured":"Seidel M, Geisler D, King JA, et al. Dynamic Changes in Local Brain Connectivity and Activity: A Longitudinal Study in Adolescent Anorexia Nervosa. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9(4):447\u201358. https:\/\/doi.org\/10.1016\/j.bpsc.2024.01.006.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"4","key":"1679_CR73","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","volume":"30","author":"TW Flanagan","year":"2018","unstructured":"Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363\u201375. https:\/\/doi.org\/10.1080\/09540261.2018.1481827.","journal-title":"Int Rev Psychiatry"},{"key":"1679_CR74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/neuro.23.003.200","volume":"3","author":"L Gautron","year":"2010","unstructured":"Gautron L, Lay\u00e9 S. Neurobiology of inflammation-associated anorexia. Front Neurosci. 2010;3:59. https:\/\/doi.org\/10.3389\/neuro.23.003.200.","journal-title":"Front Neurosci"},{"key":"1679_CR75","doi-asserted-by":"publisher","first-page":"105580","DOI":"10.1016\/j.neubiorev.2024.105580","volume":"159","author":"SJ Brooks","year":"2024","unstructured":"Brooks SJ, Dahl K, Dudley-Jones R, Schi\u00f6th HB. A neuroinflammatory compulsivity model of anorexia nervosa (NICAN). Neurosci Biobehav Rev. 2024;159:105580. https:\/\/doi.org\/10.1016\/j.neubiorev.2024.105580.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"1679_CR76","doi-asserted-by":"publisher","first-page":"e20162089","DOI":"10.1542\/peds.2016-2089","volume":"140","author":"S Zerwas","year":"2017","unstructured":"Zerwas S, Larsen JT, Petersen L, et al. Eating Disorders, Autoimmune, and Autoinflammatory Disease. Pediatrics. 2017;140(6):e20162089. https:\/\/doi.org\/10.1542\/peds.2016-2089.","journal-title":"Pediatrics"},{"key":"1679_CR77","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-019-1075-9","volume":"569","author":"R Nardou","year":"2019","unstructured":"Nardou R, Lewis EM, Rothhaas R, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019;569:116\u201320. https:\/\/doi.org\/10.1038\/s41586-019-1075-9.","journal-title":"Nature"},{"key":"1679_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2023.05.008","volume":"75","author":"A Calder","year":"2023","unstructured":"Calder A, Mock S, Friedli N, Pasi P, Hasler G. Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms. Eur Neuropsychopharmacol. 2023;75:1\u201314. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.05.008.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"1679_CR79","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.neuropsychologia.2012.01.036","volume":"50","author":"C Keating","year":"2012","unstructured":"Keating C, Tilbrook AJ, Rossell SL, Enticott PG, Fitzgerald PB. Reward processing in anorexia nervosa. Neuropsychologia. 2012;50(5):567\u201375. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2012.01.036.","journal-title":"Neuropsychologia"},{"key":"1679_CR80","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neubiorev.2015.02.012","volume":"52","author":"CB O\u2019Hara","year":"2015","unstructured":"O\u2019Hara CB, Campbell IC, Schmidt U. A reward-centred model of anorexia nervosa: a focussed narrative review of the neurological and psychophysiological literature. Neurosci Biobehav Rev. 2015;52:131\u201352. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.02.012.","journal-title":"Neurosci Biobehav Rev"},{"key":"1679_CR81","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/s41380-024-02575-9","volume":"29","author":"K Conn","year":"2024","unstructured":"Conn K, Milton LK, Huang K, et al. Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. Mol Psychiatry. 2024;29:3291\u2013304. https:\/\/doi.org\/10.1038\/s41380-024-02575-9.","journal-title":"Mol Psychiatry"},{"key":"1679_CR82","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41386-023-01545-z","volume":"48","author":"A Torrado Pacheco","year":"2023","unstructured":"Torrado Pacheco A, Olson RJ, Garza G, et al. Acute psilocybin enhances cognitive flexibility in rats. Neuropsychopharmacol. 2023;48:1011\u201320. https:\/\/doi.org\/10.1038\/s41386-023-01545-z.","journal-title":"Neuropsychopharmacol"},{"issue":"1","key":"1679_CR83","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11(1):574. https:\/\/doi.org\/10.1038\/s41398-021-01706-y. Published 2021 Nov 8.","journal-title":"Transl Psychiatry"},{"issue":"7","key":"1679_CR84","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cpr.2010.03.001","volume":"30","author":"TB Kashdan","year":"2010","unstructured":"Kashdan TB, Rottenberg J. Psychological flexibility as a fundamental aspect of health. Clin Psychol Rev. 2010;30(7):865\u201378. https:\/\/doi.org\/10.1016\/j.cpr.2010.03.001.","journal-title":"Clin Psychol Rev"},{"issue":"2","key":"1679_CR85","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jcbs.2017.02.003","volume":"6","author":"AT Gloster","year":"2017","unstructured":"Gloster AT, Meyer AH, Lieb R. Psychological flexibility as a malleable public health target: Evidence from a representative sample. J Context Behav Sci. 2017;6(2):166\u201371. https:\/\/doi.org\/10.1016\/j.jcbs.2017.02.003.","journal-title":"J Context Behav Sci"},{"key":"1679_CR86","unstructured":"Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy: The process and practice of mindful change. 2nd ed. The Guilford Press. 2012."},{"key":"1679_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","volume":"15","author":"AK Davis","year":"2020","unstructured":"Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020;15:39\u201345. https:\/\/doi.org\/10.1016\/j.jcbs.2019.11.004.","journal-title":"J Contextual Behav Sci"},{"key":"1679_CR88","doi-asserted-by":"publisher","first-page":"8833","DOI":"10.1038\/s41598-024-58318-x","volume":"14","author":"J Sloshower","year":"2024","unstructured":"Sloshower J, Zeifman RJ, Guss J, et al. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Sci Rep. 2024;14:8833. https:\/\/doi.org\/10.1038\/s41598-024-58318-x.","journal-title":"Sci Rep"},{"issue":"2","key":"1679_CR89","first-page":"211","volume":"8","author":"B Pilecki","year":"2024","unstructured":"Pilecki B, Luoma J, Lear KM. A pilot study of the effect of group-administered psilocybin on psychological flexibility and outcomes. J Psychedel Stud. 2024;8(2):211\u20138.","journal-title":"J Psychedel Stud"},{"issue":"1","key":"1679_CR90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0145445509351569","volume":"34","author":"A Masuda","year":"2010","unstructured":"Masuda A, Price M, Anderson PL, Wendell JW. Disordered Eating-Related Cognition and Psychological Flexibility as Predictors of Psychological Health Among College Students. Behav Modif. 2010;34(1):3\u201315. https:\/\/doi.org\/10.1177\/0145445509351569. (Original work published 2010).","journal-title":"Behav Modif"},{"issue":"3","key":"1679_CR91","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.eatbeh.2013.06.003","volume":"14","author":"ML Hill","year":"2013","unstructured":"Hill ML, Masuda A, Latzman RD. Body image flexibility as a protective factor against disordered eating behavior for women with lower body mass index. Eat Behav. 2013;14(3):336\u201341. https:\/\/doi.org\/10.1016\/j.eatbeh.2013.06.003.","journal-title":"Eat Behav"},{"issue":"3","key":"1679_CR92","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacol Rev. 2019;71(3):316\u201344. https:\/\/doi.org\/10.1124\/pr.118.017160.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1679_CR93","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1038\/s41598-024-52746-6","volume":"15","author":"RJ Zeifman","year":"2025","unstructured":"Zeifman RJ, Spriggs MJ, Kettner H, et al. From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS). Sci Rep. 2025;15(1):3651. https:\/\/doi.org\/10.1038\/s41598-024-52746-6.","journal-title":"Sci Rep"},{"issue":"3","key":"1679_CR94","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268\u201392. https:\/\/doi.org\/10.1007\/s00213-006-0457-5.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1679_CR95","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157\u201364. https:\/\/doi.org\/10.2174\/1874473708666150107121331.","journal-title":"Curr Drug Abuse Rev"},{"issue":"6","key":"1679_CR96","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621\u201332. https:\/\/doi.org\/10.1177\/0269881108094300.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"1679_CR97","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453\u201361. https:\/\/doi.org\/10.1177\/0269881111420188.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"1679_CR98","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.amp.2021.06.010","volume":"179","author":"V Verroust","year":"2021","unstructured":"Verroust V, Zafar R, Spriggs MJ. Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case study. Ann Med Psychol (Paris). 2021;179(8):777\u201381. https:\/\/doi.org\/10.1016\/j.amp.2021.06.010.","journal-title":"Ann Med Psychol (Paris)"},{"key":"1679_CR99","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-030-55688-2_10","volume-title":"Ayahuasca Healing and Science","author":"A Lafrance","year":"2021","unstructured":"Lafrance A, Renelli M, Fletcher J, et al. Ayahuasca as a healing tool along the continuum of recovery from eating disorders. In: Loizaga-Velder A, Tupper KW, editors. Ayahuasca Healing and Science. Cham: Springer International Publishing; 2021. pp. 189\u2013208. https:\/\/doi.org\/10.1007\/978-3-030-55688-2_10."},{"issue":"5","key":"1679_CR100","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","volume":"49","author":"A Lafrance","year":"2017","unstructured":"Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW. Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences along the Continuum of Recovery from Eating Disorders. J Psychoact Drugs. 2017;49(5):427\u201335. https:\/\/doi.org\/10.1080\/02791072.2017.1361559.","journal-title":"J Psychoact Drugs"},{"issue":"2","key":"1679_CR101","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40519-018-0619-6","volume":"25","author":"M Renelli","year":"2020","unstructured":"Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A. An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord. 2020;25(2):437\u201344. https:\/\/doi.org\/10.1007\/s40519-018-0619-6.","journal-title":"Eat Weight Disord"},{"issue":"4","key":"1679_CR102","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","volume":"26","author":"MJ Spriggs","year":"2021","unstructured":"Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord. 2021;26(4):1265\u201370. https:\/\/doi.org\/10.1007\/s40519-020-01000-8.","journal-title":"Eat Weight Disord"},{"key":"1679_CR103","doi-asserted-by":"publisher","first-page":"002216782110480","DOI":"10.1177\/00221678211048049","volume":"9","author":"A Lafrance","year":"2021","unstructured":"Lafrance A, Strahan E, Bird BM, St. Pierre M, Walsh Z. Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample. J Humanistic Psychol Published online Oct. 2021;9:00221678211048049. https:\/\/doi.org\/10.1177\/00221678211048049.","journal-title":"J Humanistic Psychol Published online Oct"},{"issue":"1","key":"1679_CR104","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.brat.2004.12.003","volume":"44","author":"JM Mond","year":"2006","unstructured":"Mond JM, Hay PJ, Rodgers B, Owen C. Eating Disorder Examination Questionnaire (EDE-Q): norms for young adult women. Behav Res Ther. 2006;44(1):53\u201362. https:\/\/doi.org\/10.1016\/j.brat.2004.12.003.","journal-title":"Behav Res Ther"},{"key":"1679_CR105","doi-asserted-by":"publisher","first-page":"102878","DOI":"10.1016\/j.nsa.2023.102878","volume":"2","author":"H Douglass","year":"2023","unstructured":"Douglass H, Spriggs M, Godfrey K, et al. Psilocybin as a treatment for anorexia nervosa: 6-week and 3-month follow-up results. Neurosci Appl. 2023;2:102878. https:\/\/doi.org\/10.1016\/j.nsa.2023.102878.","journal-title":"Neurosci Appl"},{"key":"1679_CR106","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41386-023-01751-9","volume":"49","author":"H Douglass","year":"2024","unstructured":"Douglass H, Spriggs M, Godfrey K, et al. The feasibility, safety, and potential efficacy of psilocybin with psychological support as an adjunct treatment for anorexia nervosa in adult females. Neuropsychopharmacology. 2024;49:467\u20138.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1679_CR107","doi-asserted-by":"publisher","first-page":"15","DOI":"10.61373\/pp024e.0034","volume":"1","author":"SK Peck","year":"2024","unstructured":"Peck SK, Fisher H, Kim J, Shao S, Trim J, Kaye WH. Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help. Psychedelics. 2024;1(1):15\u20138. https:\/\/doi.org\/10.61373\/pp024e.0034.","journal-title":"Psychedelics"},{"issue":"8","key":"1679_CR108","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","volume":"29","author":"SK Peck","year":"2023","unstructured":"Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29(8):1947\u201353. https:\/\/doi.org\/10.1038\/s41591-023-02455-9.","journal-title":"Nat Med"},{"key":"1679_CR109","unstructured":"Gukasyan N, Shreyer CC, Casimano MP et al. Psilocybin-assisted therapy for anorexia nervosa: a multi-session open-label pilot study. In press."},{"issue":"9","key":"1679_CR110","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/eat.24223","volume":"57","author":"M S\u00f8eby","year":"2024","unstructured":"S\u00f8eby M, Gribsholt SB, Clausen L, Richelsen B. Overall and cause-specific mortality in anorexia nervosa; impact of psychiatric comorbidity and sex in a 40-year follow-up study. Int J Eat Disord. 2024;57(9):1842\u201353. https:\/\/doi.org\/10.1002\/eat.24223.","journal-title":"Int J Eat Disord"},{"issue":"2","key":"1679_CR111","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1192\/bjp.bp.107.048686","volume":"194","author":"E Wentz","year":"2009","unstructured":"Wentz E, Gillberg IC, Anckars\u00e4ter H, Gillberg C, R\u00e5stam M. Adolescent-onset anorexia nervosa: 18-year outcome. Br J Psychiatry. 2009;194(2):168\u201374. https:\/\/doi.org\/10.1192\/bjp.bp.107.048686.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"1679_CR112","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/jcp.v67n11101","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735\u201340. https:\/\/doi.org\/10.4088\/jcp.v67n11101.","journal-title":"J Clin Psychiatry"},{"key":"1679_CR113","doi-asserted-by":"publisher","first-page":"152619","DOI":"10.1016\/j.comppsych.2025.152619","volume":"142","author":"L Pellegrini","year":"2025","unstructured":"Pellegrini L, Fineberg NA, O\u2019Connor S, et al. Single-dose (10\u00a0mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Compr Psychiatr. 2025;142:152619. https:\/\/doi.org\/10.1016\/j.comppsych.2025.152619.","journal-title":"Compr Psychiatr"},{"key":"1679_CR114","doi-asserted-by":"publisher","first-page":"e078084","DOI":"10.1136\/bmj-2023-078084","volume":"385","author":"AM Metaxa","year":"2024","unstructured":"Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084. https:\/\/doi.org\/10.1136\/bmj-2023-078084. Published 2024 May 1.","journal-title":"BMJ"},{"key":"1679_CR115","doi-asserted-by":"publisher","unstructured":"Izmi N, Carhart-Harris RL, Kettner H. Psychological effects of psychedelics in adolescents. Front Child Adolesc Psychiatry. 2024;3. https:\/\/doi.org\/10.3389\/frcha.2024.1364617.","DOI":"10.3389\/frcha.2024.1364617"},{"issue":"1","key":"1679_CR116","doi-asserted-by":"publisher","first-page":"21927","DOI":"10.1038\/s41598-022-25658-5","volume":"12","author":"G Jones","year":"2022","unstructured":"Jones G, Arias D, Nock M. Associations between MDMA\/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents. Sci Rep. 2022;12(1):21927. https:\/\/doi.org\/10.1038\/s41598-022-25658-5.","journal-title":"Sci Rep"},{"issue":"1","key":"1679_CR117","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/13638490601106277","volume":"10","author":"J Sigafoos","year":"2007","unstructured":"Sigafoos J, Green VA, Edrisinha C, Lancioni GE. Flashback to the 1960s: LSD in the treatment of autism. Dev Neurorehabil. 2007;10(1):75\u201381. https:\/\/doi.org\/10.1080\/13638490601106277.","journal-title":"Dev Neurorehabil"},{"issue":"2","key":"1679_CR118","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/02791072.2005.10399792","volume":"37","author":"DX Da Silveira","year":"2005","unstructured":"Da Silveira DX, Grob CS, de Rios MD, et al. Ayahuasca in adolescence: a preliminary psychiatric assessment. J Psychoact Drugs. 2005;37(2):129\u201333. https:\/\/doi.org\/10.1080\/02791072.2005.10399792.","journal-title":"J Psychoact Drugs"},{"issue":"2","key":"1679_CR119","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/02791072.2005.10399791","volume":"37","author":"E Doering-Silveira","year":"2005","unstructured":"Doering-Silveira E, Lopez E, Grob CS, et al. Ayahuasca in adolescence: a neuropsychological assessment. J Psychoact Drugs. 2005;37(2):123\u20138. https:\/\/doi.org\/10.1080\/02791072.2005.10399791.","journal-title":"J Psychoact Drugs"},{"issue":"12","key":"1679_CR120","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397. https:\/\/doi.org\/10.1177\/0269881116675513.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1679_CR121","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/00048674241289024","volume":"59","author":"RR Freitas","year":"2025","unstructured":"Freitas RR, Gotsis ES, Gallo AT, Fitzgibbon BM, Bailey NW, Fitzgerald PB. The safety of psilocybin-assisted psychotherapy: A systematic review. Aust N Z J Psychiatry. 2025;59(2):128\u201351. https:\/\/doi.org\/10.1177\/00048674241289024.","journal-title":"Aust N Z J Psychiatry"},{"issue":"8","key":"1679_CR122","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/10600280231205645","volume":"58","author":"D Kaminski","year":"2024","unstructured":"Kaminski D, Reinert JP. The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review. Ann Pharmacother. 2024;58(8):811\u201326. https:\/\/doi.org\/10.1177\/10600280231205645.","journal-title":"Ann Pharmacother"},{"key":"1679_CR123","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143\u201366. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1679_CR124","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40337-024-01005-z","volume":"12","author":"AE Downey","year":"2024","unstructured":"Downey AE, Chaphekar AV, Woolley J, Raymond-Flesch M. Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians. J Eat Disorders. 2024;12(1):49. https:\/\/doi.org\/10.1186\/s40337-024-01005-z.","journal-title":"J Eat Disorders"},{"issue":"14","key":"1679_CR125","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.3390\/jcm13144084","volume":"13","author":"E Gkintoni","year":"2024","unstructured":"Gkintoni E, Kourkoutas E, Vassilopoulos SP, Mousi M. Clinical Intervention Strategies and Family Dynamics in Adolescent Eating Disorders: A Scoping Review for Enhancing Early Detection and Outcomes. J Clin Med. 2024;13(14):4084. https:\/\/doi.org\/10.3390\/jcm13144084. Published 2024 Jul 12.","journal-title":"J Clin Med"},{"key":"1679_CR126","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13034-025-00930-4","volume":"19","author":"S Forsberg","year":"2025","unstructured":"Forsberg S, Downey AE, Bruett LD, et al. Leveraging family and caregiver support in psychedelic-assisted therapy: considerations for the treatment of adolescents. Child Adolesc Psychiatry Ment Health. 2025;19:64. https:\/\/doi.org\/10.1186\/s13034-025-00930-4.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"3","key":"1679_CR127","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/jmft.12351","volume":"45","author":"M Foroughe","year":"2019","unstructured":"Foroughe M, Stillar A, Goldstein L, Dolhanty J, Goodcase ET, Lafrance A. Brief Emotion Focused Family Therapy: An Intervention for Parents of Children and Adolescents with Mental Health Issues. J Marital Fam Ther. 2019;45(3):410\u201330. https:\/\/doi.org\/10.1111\/jmft.12351.","journal-title":"J Marital Fam Ther"},{"key":"1679_CR128","doi-asserted-by":"publisher","first-page":"887255","DOI":"10.3389\/fpsyg.2022.887255","volume":"13","author":"M Cavarra","year":"2022","unstructured":"Cavarra M, Falzone A, Ramaekers JG, Kuypers KPC, Mento C. Psychedelic-Assisted Psychotherapy\u2014A Systematic Review of Associated Psychological Interventions. Front Psychol. 2022;13:887255. https:\/\/doi.org\/10.3389\/fpsyg.2022.887255.","journal-title":"Front Psychol"},{"issue":"11","key":"1679_CR129","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00787-023-02310-9","volume":"33","author":"S Kangaslampi","year":"2024","unstructured":"Kangaslampi S, Zijlmans J. MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations. Eur Child Adolesc Psychiatry. 2024;33(11):3753\u201364. https:\/\/doi.org\/10.1007\/s00787-023-02310-9.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"10","key":"1679_CR130","doi-asserted-by":"publisher","first-page":"e0293349","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS ONE. 2023;18(10):e0293349. https:\/\/doi.org\/10.1371\/journal.pone.0293349.","journal-title":"PLoS ONE"},{"issue":"6","key":"1679_CR131","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamapsychiatry.2024.0184","volume":"81","author":"M Marks","year":"2024","unstructured":"Marks M, Brendel RW, Shachar C, Cohen IG. Essentials of Informed Consent to Psychedelic Medicine. JAMA Psychiatry. 2024;81(6):611\u20137. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0184.","journal-title":"JAMA Psychiatry"},{"key":"1679_CR132","doi-asserted-by":"publisher","unstructured":"Bradberry MM, Appelbaum PS, Gukasyan N. Informed consent in psychedelic-assisted therapy. Curr Top Behav Neurosci Published online Dec. 2024;31. https:\/\/doi.org\/10.1007\/7854_2024_559.","DOI":"10.1007\/7854_2024_559"},{"issue":"6","key":"1679_CR133","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3109\/15622975.2011.639804","volume":"14","author":"ME Roberts","year":"2013","unstructured":"Roberts ME, Tchanturia K, Treasure JL. Is attention to detail a similarly strong candidate endophenotype for anorexia nervosa and bulimia nervosa? World J Biol Psychiatry. 2013;14(6):452\u201363. https:\/\/doi.org\/10.3109\/15622975.2011.639804.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"1679_CR134","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/eip.12170","volume":"9","author":"J Treasure","year":"2015","unstructured":"Treasure J, Stein D, Maguire S. Has the time come for a staging model to map the course of eating disorders from high risk to severe enduring illness? An examination of the evidence. Early Interv Psychiat. 2015;9(3):173\u201384. https:\/\/doi.org\/10.1111\/eip.12170.","journal-title":"Early Interv Psychiat"},{"issue":"1","key":"1679_CR135","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2352-4642(22)00236-X","volume":"7","author":"K Tsiandoulas","year":"2023","unstructured":"Tsiandoulas K, McSheffrey G, Fleming L, et al. Ethical tensions in the treatment of youth with severe anorexia nervosa. Lancet Child Adolesc Health. 2023;7(1):69\u201376. https:\/\/doi.org\/10.1016\/S2352-4642(22)00236-X.","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"1679_CR136","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s40337-024-01174","volume":"12","author":"TR Brown","year":"2024","unstructured":"Brown TR, Jansen MO, Hirsch D, Amir H, Duncan AE, Nicol GE. Hiding in plain sight: eating disorders in diverse populations - a case for comprehensive medical education. J Eat Disorders. 2024;12(1):216. https:\/\/doi.org\/10.1186\/s40337-024-01174.","journal-title":"J Eat Disorders"},{"key":"1679_CR137","doi-asserted-by":"publisher","first-page":"102711","DOI":"10.1016\/j.eclinm.2024.102711","volume":"74","author":"ME Hughes","year":"2024","unstructured":"Hughes ME, Garcia-Romeu A. Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. EClinicalMedicine. 2024;74:102711. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102711.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1679_CR138","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s11469-023-01160-5","volume":"22","author":"MT Williams","year":"2024","unstructured":"Williams MT, Cabral V, Faber S. Psychedelics and racial justice. Int J Ment Health Addict. 2024;22(2):880\u201396. https:\/\/doi.org\/10.1007\/s11469-023-01160-5.","journal-title":"Int J Ment Health Addict"},{"key":"1679_CR139","doi-asserted-by":"publisher","unstructured":"van Vugt AS, Zijlmans J, Lindauer R, van Dam L. MDMA-assisted psychotherapy with adolescents suffering from PTSD: Do or don\u2019t? a qualitative study with youth, parents, and clinicians. Drug Science, Policy and Law. 2023;9:20503245231198477. https:\/\/doi.org\/10.1177\/20503245231198477","DOI":"10.1177\/20503245231198477"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-026-01679-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-026-01679-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-026-01679-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:55:07Z","timestamp":1778723707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-026-01679-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1007\/s11920-026-01679-z","relation":{},"ISSN":["1535-1645"],"issn-type":[{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no financial interests to disclose. Jamarie Geller has been involved in two clinical trials involving the use of psilocybin-assisted psychotherapy for fibromyalgia and treatment-resistant depression at the University of Michigan. Stephanie Knatz-Peck is a senior clinical consultant for Compass Pathways, funder of the Phase 1 anorexia nervosa clinical trial noted in this manuscript. Natalie Gukasyan reports current research support from Reunion Neuroscience and Helus Pharma, and personal fees from Multidisciplinary Association for Psychedelic Studies, outside the submitted work. Marissa Raymond-Flesch reports receiving philanthropic support from private donors to conduct a study of psilocybin for the treatment of anorexia nervosa in young adults.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}